Plain-English translation of NCT06831136 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new combination treatment for advanced pancreatic cancer that cannot be surgically removed. The approach combines three elements: a procedure called endoscopic ultrasound radiofrequency ablation (which uses heat to destroy tumors), standard chemotherapy drugs, and pembrolizumab, an immunotherapy medication that helps your body's immune system fight cancer. Researchers want to see if combining these treatments together is safe and effective.
Pancreatic cancer that has spread or cannot be removed with surgery is very difficult to treat, and current treatments have limited success. This trial is exploring whether adding the heat ablation procedure to standard cancer medications might give patients a better chance at controlling their disease.
You likely qualify if…
You likely don't qualify if…
You would receive standard chemotherapy drugs along with pembrolizumab infusions on a regular schedule. At the start of treatment, you would undergo the endoscopic ultrasound radiofrequency ablation procedure, which uses ultrasound guidance to deliver heat to the tumor(s) inside or near your pancreas. You would have multiple clinic visits for infusions, blood tests, and imaging scans to monitor how the cancer is responding. The study involves 24 participants total, and your participation would continue as long as the treatment appears to be helping and you are tolerating it well.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States